<DOC>
	<DOCNO>NCT02000687</DOCNO>
	<brief_summary>This single-center , prospective , open label study islet transplant recipient follow islet graft loss .</brief_summary>
	<brief_title>Long Term Surveillance Islet Transplant Recipients Following Complete Graft Loss</brief_title>
	<detailed_description>After complete islet graft loss determine , patient 's maintenance immunosuppression ( i.e . sirolimus , tacrolimus , MMF and/or Myfortic® ) discontinue monitor 10 year thereafter , appearance allosensitization use panel reactive antibody ( PRA ) level monitor persistence elevate PRA level . Primary objective determine rate allosensitization patient 3 year fail islet transplantation ( i.e . stimulate c-peptide &lt; 0.3mg/mL ) monitor persistence elevate PRA level ( ≥ 20 % ) year 3 , 6 , 9 . Timing , frequency level change PRA monitor immunosuppression discontinue .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>1 . History least one islet alone transplant ( ie islet transplant absence organ transplant ) . 1 . Inability provide write informed consent . 2 . Mentally unstable and/or unable comply procedure study protocol . 3 . History solid organ transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>